Glaucoma

Complex MONDO:0005041 Show in embeddings browser Ophthalmological Disease

Glaucoma is a group of progressive optic neuropathies characterized by retinal ganglion cell death and degeneration of the optic nerve, producing characteristic cupping of the optic disc and corresponding visual field loss. Elevated intraocular pressure, usually from impaired aqueous humor outflow through the trabecular meshwork (open-angle) or from physical closure of the drainage angle (angle-closure), is the principal modifiable risk factor that drives mechanical and ischemic stress at the optic nerve head. Because the ganglion cell loss is irreversible and often asymptomatic until advanced, glaucoma is a leading cause of irreversible blindness worldwide.

Ask OpenScientist

Ask a research question about Glaucoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
5
Phenotypes
4
Genes
8
Medical Actions
4
Subtypes
5
Datasets
3
References
2
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
◆

Subtypes

4
Primary Open-Angle Glaucoma
Most common form, gradual onset with open drainage angle.
Angle-Closure Glaucoma
Blocked drainage angle, can be acute or chronic.
Normal-Tension Glaucoma
Optic nerve damage despite normal IOP.
Secondary Glaucoma
Due to other conditions (trauma, steroids, uveitis).
⚙

Pathophysiology

4
Elevated Intraocular Pressure
Impaired aqueous humor drainage through trabecular meshwork leads to increased IOP in most cases. Elevated pressure damages retinal ganglion cells and optic nerve.
Fluid Homeostasis GO:0050891 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Fluid Homeostasis, annotated with multicellular organismal-level water homeostasis (GO:0050891). GO:0050891 is a biological process from the Gene Ontology.
Anterior Chamber of Eye UBERON:0001766 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Anterior Chamber of Eye, annotated with anterior chamber of eyeball (UBERON:0001766). UBERON:0001766 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:26497784 SUPPORT
"Elevated intraocular pressure and aging, the main risk factors for glaucoma, accelerate RGC apoptosis."
Identifies elevated IOP as a main risk factor that accelerates retinal ganglion cell apoptosis in glaucoma.
Retinal Ganglion Cell Death
Progressive apoptosis of retinal ganglion cells leads to irreversible vision loss. Mechanical stress, ischemia, and excitotoxicity contribute to cell death.
Retinal Ganglion Cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Retinal Ganglion Cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology.
Apoptosis GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Apoptosis, annotated with apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology.
Retina UBERON:0000966 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Retina (UBERON:0000966). UBERON:0000966 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (3 references)
PMID:26497784 SUPPORT
"Apoptosis of retinal ganglion cells (RGCs) in glaucoma causes progressive visual field loss, making it the primary cause of irreversible blindness worldwide."
Establishes that RGC apoptosis is the direct cause of visual field loss in glaucoma, confirming the central role of programmed cell death in disease pathogenesis.
PMID:26302410 SUPPORT
"A glaucoma-associated mutant of optineurin, E50K, impairs autophagy as well as vesicle trafficking, leading to death of retinal cells by apoptosis."
Links OPTN mutations to RGC apoptosis through impaired autophagy, providing a molecular mechanism for how genetic variants cause retinal ganglion cell death.
PMID:37542647 SUPPORT
"Glaucoma is a leading cause of permanent blindness worldwide and is characterized by neurodegeneration linked to progressive retinal ganglion cell (RGC) death, axonal damage, and neuroinflammation."
Confirms that RGC death is a hallmark of glaucoma neurodegeneration and highlights the role of neuroinflammation in the degenerative process.
Optic Nerve Degeneration
Loss of ganglion cell axons causes characteristic optic disc cupping. Progressive nerve fiber layer loss detectable before symptomatic visual field loss.
Optic Nerve UBERON:0000941 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Optic Nerve, annotated with cranial nerve II (UBERON:0000941). UBERON:0000941 is an anatomical location from the Uberon multi-species anatomy ontology. Optic Disc UBERON:0001783 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Optic Disc (UBERON:0001783). UBERON:0001783 is an anatomical location from the Uberon multi-species anatomy ontology.
Trabecular Meshwork Dysfunction
Age-related changes, oxidative stress, and altered extracellular matrix reduce outflow facility. Increased resistance to aqueous outflow.
Trabecular Meshwork Cell CL:0002367 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Trabecular Meshwork Cell (CL:0002367). CL:0002367 is a cell type from the Cell Ontology.
Trabecular Meshwork UBERON:0005969 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Trabecular Meshwork, annotated with eye trabecular meshwork (UBERON:0005969). UBERON:0005969 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:10617907 SUPPORT In Vitro
"Myocilin gene is expressed clearly in the trabecular meshwork cells of both glaucomatous and nonglaucomatous eyes."
Confirms MYOC expression in trabecular meshwork cells, but expression alone only indirectly supports dysfunction. In situ RNA hybridization on ex vivo human trabecular meshwork specimens, hence IN_VITRO; note the signal was present in nonglaucomatous eyes too.
PMID:37217093 SUPPORT Other
"The prevailing pathogenic mechanism involves a gain of toxic function whereby mutant myocilin aggregates intracellularly instead of being secreted, which causes cell stress and an early timeline for TM cell death, elevated intraocular pressure, and subsequent glaucoma-associated retinal degeneration."
Regraded to PARTIAL: this describes the Mendelian MYOC misfolding mechanism, a distinct route to trabecular meshwork cell death, whereas this node asserts the age-related change, oxidative stress and altered extracellular matrix route. It establishes that trabecular meshwork dysfunction raises intraocular pressure but not the specific upstream mechanism claimed here, matching the PARTIAL grade already used on the companion MYOC expression item. Tagged OTHER because this is a narrative review stating the prevailing consensus mechanism rather than reporting primary human, animal or cell data.
●

Phenotypes

5
Eye 4
Visual Field Loss VERY_FREQUENT Visual field defect HP:0001123 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual Field Defect (HP:0001123). HP:0001123 is a phenotype from the Human Phenotype Ontology.
Peripheral vision first
Show evidence (1 reference)
PMID:26497784 SUPPORT
"Apoptosis of retinal ganglion cells (RGCs) in glaucoma causes progressive visual field loss, making it the primary cause of irreversible blindness worldwide."
Directly links RGC apoptosis to progressive visual field loss, the cardinal clinical manifestation of glaucoma.
Optic Disc Cupping VERY_FREQUENT Optic atrophy HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic Atrophy (HP:0000648). HP:0000648 is a phenotype from the Human Phenotype Ontology.
Elevated Intraocular Pressure FREQUENT Abnormal intraocular pressure HP:0012632 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated IOP, annotated with Abnormal intraocular pressure (HP:0012632). HP:0012632 is a phenotype from the Human Phenotype Ontology.
Not present in normal-tension glaucoma
Show evidence (1 reference)
PMID:37217093 SUPPORT
"The prevailing pathogenic mechanism involves a gain of toxic function whereby mutant myocilin aggregates intracellularly instead of being secreted, which causes cell stress and an early timeline for TM cell death, elevated intraocular pressure, and subsequent glaucoma-associated retinal degeneration."
Links mutant MYOC to elevated IOP through trabecular meshwork cell death, establishing the mechanistic connection between genetic mutations and the elevated pressure phenotype.
Halos Around Lights OCCASIONAL Visual impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual Impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
More common in angle-closure
Constitutional 1
Eye Pain OCCASIONAL Ocular pain HP:0200026 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Eye Pain, annotated with Ocular pain (HP:0200026). HP:0200026 is a phenotype from the Human Phenotype Ontology.
Acute angle-closure glaucoma
🧬

Genetic Associations

4
MYOC (Causative)
Gene: MYOC hgnc:7610 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MYOC (hgnc:7610). hgnc:7610 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:37217093 SUPPORT Other
"Mutations in the gene MYOC account for approximately 5% of cases of primary open angle glaucoma (POAG)."
Establishes MYOC as a causative gene for POAG, accounting for a significant proportion of cases. Tagged OTHER: this is a narrative review restating an established figure rather than reporting primary data.
PMID:37217093 SUPPORT Other
"While myocilin is expressed in numerous tissues, mutant myocilin is only associated with disease in the anterior segment of the eye, in the trabecular meshwork."
Demonstrates tissue-specific pathogenicity of MYOC mutations in the trabecular meshwork of the eye. Tagged OTHER for the same reason as the companion item — review synthesis, not primary observation.
OPTN (Causative)
Gene: OPTN hgnc:17142 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is OPTN (hgnc:17142). hgnc:17142 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (3 references)
PMID:26302410 SUPPORT In Vitro
"Certain mutations in optineurin (gene OPTN) are associated with primary open angle glaucoma."
Regraded to PARTIAL: the snippet establishes an association between OPTN mutations and primary open-angle glaucoma, but says nothing about normal-tension glaucoma, which is the scope this entry records, and "associated with" does not by itself settle causative-versus-risk-allele typing. Tagged IN_VITRO — the study characterizes autophagy defects in cultured cells expressing mutant optineurin.
PMID:16043855 SUPPORT Human Clinical
"All 11 subjects had normal tension glaucoma (NTG), with presenting and highest IOP of 15.3 +/- 3.0 and 16.5 +/- 2.5 mm Hg (+/-SD) on diurnal testing."
Supplies the normal-tension-glaucoma-specific association that the note on this entry previously recorded as an outstanding gap: every E50K carrier in this clinical series had NTG, at quantified normal pressures.
PMID:26302410 SUPPORT In Vitro
"Thus, an optimum level of optineurin-mediated autophagy is crucial for survival of retinal cells, and impaired autophagy is likely to contribute to glaucoma pathogenesis."
Explains how OPTN variants contribute to glaucoma through dysregulated autophagy in retinal cells. This is the paper's own mechanistic conclusion, so SUPPORT stands; the cell-based experimental basis is recorded by the IN_VITRO tag.
WDR36 (Risk Factor)
Gene: WDR36 hgnc:30696 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is WDR36 (hgnc:30696). hgnc:30696 is a gene from the HUGO Gene Nomenclature Committee.
CAV1/CAV2 (Risk Factor)
💊

Medical Actions

8
Prostaglandin Analogs
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986), qualified as route of administration topical route of administration. NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
First-line topical drops that increase uveoscleral outflow.
Show evidence (2 references)
PMID:8942890 SUPPORT Human Clinical
"Purpose: To determine efficacy and safety of latanoprost, a prostaglandin analog for glaucoma, during 1 year of treatment."
This clinical trial directly supports prostaglandin analog therapy, using latanoprost as a representative first-line agent for glaucoma.
PMID:8942890 SUPPORT Human Clinical
"Conclusion: Latanoprost safely and effectively reduces IOP for 1 year in patients of diverse nationalities, providing further evidence for its usefulness in chronic glaucoma therapy."
This provides direct human evidence that topical latanoprost produces sustained intraocular pressure lowering in glaucoma therapy.
Beta-Blockers
Action: beta-blocker therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is beta-blocker therapy, annotated with Pharmacotherapy (NCIT:C15986), qualified as route of administration topical route of administration. NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: timolol CHEBI:39465 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses timolol (CHEBI:39465). CHEBI:39465 is a therapeutic agent from Chemical Entities of Biological Interest.
Topical beta-blocker drops reduce aqueous humor production.
Show evidence (2 references)
PMID:16750466 SUPPORT Human Clinical
"Objective: The objective of this study was to assess the hypotensive efficacy of timolol maleate 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% ophthalmic solution, administered in conjunction with travoprost 0.004%, in patients with primary open-angle laucoma (OAG) or ocular hypertension..."
This randomized study directly evaluates topical timolol as an intraocular pressure-lowering treatment in open-angle glaucoma or ocular hypertension.
PMID:16750466 SUPPORT Human Clinical
"Conclusion: Brinzolamide 1% and timolol maleate 0.5% treatment were both associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when administered as a nonfixed adjuvant to travoprost 0.004% in the treatment of patients with OAG and OHT whose IOP was inadequately..."
This supports timolol as an effective adjunctive topical beta-blocker therapy for additional pressure reduction.
Alpha Agonists
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986), qualified as route of administration topical route of administration. NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: brimonidine CHEBI:3175 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses brimonidine (CHEBI:3175). CHEBI:3175 is a therapeutic agent from Chemical Entities of Biological Interest.
Topical alpha-2 agonist drops reduce aqueous production and modestly increase outflow.
Show evidence (2 references)
PMID:14660453 SUPPORT Human Clinical
"Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%."
This randomized trial directly supports brimonidine as a therapeutic alpha agonist used in primary open-angle glaucoma.
PMID:14660453 SUPPORT Human Clinical
"Results: IOP reduction was similar for both groups (p<0.05)."
Regraded to PARTIAL: this is a non-difference result between brimonidine and timolol in a 16-patient trial, so it shows brimonidine is not inferior to an established agent rather than quantifying clinically meaningful intraocular pressure lowering on its own.
Carbonic Anhydrase Inhibitors
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986), qualified as route of administration topical route of administration. NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: dorzolamide CHEBI:4702 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dorzolamide (CHEBI:4702). CHEBI:4702 is a therapeutic agent from Chemical Entities of Biological Interest. brinzolamide CHEBI:3176 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses brinzolamide (CHEBI:3176). CHEBI:3176 is a therapeutic agent from Chemical Entities of Biological Interest.
Topical carbonic anhydrase inhibitors reduce aqueous humor production.
Show evidence (2 references)
PMID:16750466 SUPPORT Human Clinical
"Objective: The objective of this study was to assess the hypotensive efficacy of timolol maleate 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% ophthalmic solution, administered in conjunction with travoprost 0.004%, in patients with primary open-angle laucoma (OAG) or ocular hypertension..."
This randomized study directly evaluates brinzolamide, a topical carbonic anhydrase inhibitor, as an IOP-lowering therapy in glaucoma or ocular hypertension.
PMID:16750466 SUPPORT Human Clinical
"Conclusion: Brinzolamide 1% and timolol maleate 0.5% treatment were both associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when administered as a nonfixed adjuvant to travoprost 0.004% in the treatment of patients with OAG and OHT whose IOP was inadequately..."
This supports topical carbonic anhydrase inhibition, represented here by brinzolamide, as an effective adjunctive strategy for lowering intraocular pressure.
Rho Kinase Inhibitors
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986), qualified as route of administration topical route of administration. NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Topical rho kinase inhibitors improve trabecular outflow and lower intraocular pressure.
Show evidence (2 references)
PMID:29199013 SUPPORT Human Clinical
"Purpose: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension."
This phase 3 clinical program directly supports rho kinase inhibitor therapy using netarsudil in open-angle glaucoma or ocular hypertension.
PMID:29199013 SUPPORT Human Clinical
"Conclusions: In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma."
This supports netarsudil-based rho kinase inhibition as an effective and tolerated topical treatment option.
Laser Trabeculoplasty
SLT increases trabecular outflow.
Show evidence (1 reference)
PMID:30862377 SUPPORT Human Clinical
"At 36 months, 74·2% (95% CI 69·3-78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target."
This randomized trial supports selective laser trabeculoplasty as an effective drop-sparing treatment strategy in open-angle glaucoma or ocular hypertension.
Trabeculectomy
Action: trabeculectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is trabeculectomy, annotated with Surgical Construction of Filtration Bleb (NCIT:C220170). NCIT:C220170 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Construction of Filtration Bleb NCIT:C220170
Incisional filtration surgery for advanced or medically uncontrolled glaucoma.
Show evidence (2 references)
PMID:33980505 SUPPORT Human Clinical
"Interventions: Mitomycin C augmented trabeculectomy (n=227) and escalating medical management with intraocular pressure reducing drops (n=226)"
This randomized trial directly evaluates trabeculectomy as a primary interventional treatment for advanced open-angle glaucoma.
PMID:33980505 SUPPORT Human Clinical
"Conclusion: Primary trabeculectomy had similar quality of life and safety outcomes and achieved a lower intraocular pressure compared with primary medication."
This supports trabeculectomy as a clinically effective pressure-lowering option in advanced glaucoma.
MIGS
Microstent-based and related minimally invasive glaucoma surgery options can reduce medication burden and improve pressure control.
Show evidence (2 references)
PMID:33166551 SUPPORT Human Clinical
"Purpose: To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone."
This randomized trial directly studies a representative minimally invasive glaucoma surgery device in primary open-angle glaucoma.
PMID:33166551 SUPPORT Human Clinical
"Conclusions: Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at 3 years."
This supports MIGS as a pressure-lowering and medication-sparing surgical option in appropriately selected open-angle glaucoma.
🌍

Environmental Factors

5
Age
Major risk factor, increases after 40
Show evidence (1 reference)
PMID:2056646 SUPPORT Human Clinical
"Rates among blacks ranged from 1.23% in those aged 40 through 49 years to 11.26% in those 80 years or older"
Population-based survey of 5,308 participants, showing a roughly nine-fold prevalence gradient across the age range sampled. PARTIAL for two reasons: the survey enrols only from age 40, so it cannot evidence 40 as a threshold, and its subject is racial variation rather than age.
Family History
First-degree relatives at ~4-7x increased risk (siblings RR 3.8, parents RR 6.3, children RR 6.8)
Show evidence (1 reference)
PMID:20858511 SUPPORT Human Clinical
"siblings (RR=3.76 (95% CI 2.66-5.31)), parents (RR=6.25 (95% CI 3.94-9.9)) and children (RR=6.77 (95% CI 3.39-13.5))"
Case-control analysis over 1M linked records. The note previously said 4-9x; the measured first-degree relative risks are 3.8-6.8, so the range has been corrected to what the citation supports.
African Ancestry
Higher prevalence and severity
Show evidence (1 reference)
PMID:24974815 SUPPORT Human Clinical
"people of African ancestry were more likely to have POAG than people of European ancestry (OR, 2.80; 95% CrI, 1.83-4.06)"
Meta-analysis of 50 population-based studies, adjusted for age, gender, habitation type and study year. PARTIAL because it evidences the prevalence half of this annotation but not the severity half.
Myopia
Risk factor for open-angle glaucoma
Show evidence (1 reference)
PMID:34648776 SUPPORT Human Clinical
"For each unit (1-D) increase in myopia, the risk of glaucoma increases by approximately 20%"
Dose-response meta-analysis over 514,265 individuals; the risk accelerates nonlinearly beyond about -6 D, reaching OR 4.14 for high myopia.
Corticosteroid Use
corticosteroid exposure ECTO:0000173 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is corticosteroid exposure, annotated with exposure to corticosteroid (ECTO:0000173). ECTO:0000173 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Can induce steroid glaucoma
Show evidence (1 reference)
PMID:26002945 SUPPORT Human Clinical
"Of 1259 cases of paediatric glaucoma presenting at our centre over 5 years, 59 children (4.7%) were diagnosed with SIG"
Clinical series establishing steroid-induced glaucoma as a distinct entity and quantifying its share of paediatric glaucoma; 87% followed topical steroids prescribed for vernal keratoconjunctivitis.
🔬

Biochemical Markers

1
Intraocular Pressure (Elevated)
Context: Greater than 21 mmHg in most cases
📊

Related Datasets

5
Chromatin topology dynamics of dexamethasone-treated trabecular meshwork identifies 78 causal genes for intraocular pressure and primary open angle glaucoma geo:GSE301525
human MULTI OMICS n=131
PMID:41890121
Identified by GEO DataSets index search for Glaucoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
WTCCC2 project Glaucoma (GL) samples ega:EGAS00001000624
A WTCCC2 genome-wide association study for glaucoma (GL) in Australian individuals of European descent.
human
PMID:23836780
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Glaucoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Human Optic Nerve Glaucoma and Control Lipidomes metabolomics_workbench:ST001442
Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Glaucoma"). Retrieved 2026-08-02.
Comparative shotgun proteomics of aqueous humor for cataract, glaucoma and pseudoexfoliation eye disorders. massive:MSV000080838
The aim of this work was to characterize proteome of aqueous humor from subjects with various eye conditions such as cataract, glaucoma and pseudoexfoliation syndrome by high-resolution chromate-mass-spectrometry. Twenty nine human aqueous humor samples were processed by shotgun proteomics. Data was searched using MaxQuant package. Totally, 263 protein groups were identified. Label-free quantitation reported some differentially expressed proteins in aqueous humor proteome for the aforementioned eye diseases.
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Glaucoma"). Retrieved 2026-08-02.
Retinal proteomic profiling in the course of experimental glaucoma massive:MSV000081757
Intraocular pressure was elevated through episkleral vein occlusion by thermic cauterization of SD rats. Animals were further sacrificed after different periods of elevated IOP and the retinal proteins were investigated for alterations regarding the relative protein level in this experimental model of glaucoma.
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Glaucoma"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Glaucoma
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Glaucoma is a group of progressive optic neuropathies characterized by
  retinal ganglion cell death and degeneration of the optic nerve, producing
  characteristic cupping of the optic disc and corresponding visual field loss.
  Elevated intraocular pressure, usually from impaired aqueous humor outflow
  through the trabecular meshwork (open-angle) or from physical closure of the
  drainage angle (angle-closure), is the principal modifiable risk factor that
  drives mechanical and ischemic stress at the optic nerve head. Because the
  ganglion cell loss is irreversible and often asymptomatic until advanced,
  glaucoma is a leading cause of irreversible blindness worldwide.
category: Complex
parents:
- Ophthalmological Disease
disease_term:
  preferred_term: glaucoma
  term:
    id: MONDO:0005041
    label: glaucoma
has_subtypes:
- name: Primary Open-Angle Glaucoma
  description: Most common form, gradual onset with open drainage angle.
- name: Angle-Closure Glaucoma
  description: Blocked drainage angle, can be acute or chronic.
- name: Normal-Tension Glaucoma
  description: Optic nerve damage despite normal IOP.
- name: Secondary Glaucoma
  description: Due to other conditions (trauma, steroids, uveitis).
pathophysiology:
- name: Elevated Intraocular Pressure
  description: >
    Impaired aqueous humor drainage through trabecular meshwork
    leads to increased IOP in most cases. Elevated pressure damages
    retinal ganglion cells and optic nerve.
  locations:
  - preferred_term: Anterior Chamber of Eye
    term:
      id: UBERON:0001766
      label: anterior chamber of eyeball
  biological_processes:
  - preferred_term: Fluid Homeostasis
    term:
      id: GO:0050891
      label: multicellular organismal-level water homeostasis
  evidence:
  - reference: PMID:26497784
    reference_title: "Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms."
    supports: SUPPORT
    snippet: "Elevated intraocular pressure and aging, the main risk factors for glaucoma, accelerate RGC apoptosis."
    explanation: Identifies elevated IOP as a main risk factor that accelerates retinal ganglion cell apoptosis in glaucoma.
- name: Retinal Ganglion Cell Death
  conforms_to: "glaucoma_optic_neuropathy#Retinal Ganglion Cell Apoptosis"
  description: >
    Progressive apoptosis of retinal ganglion cells leads to
    irreversible vision loss. Mechanical stress, ischemia, and
    excitotoxicity contribute to cell death.
  locations:
  - preferred_term: Retina
    term:
      id: UBERON:0000966
      label: retina
  cell_types:
  - preferred_term: Retinal Ganglion Cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  biological_processes:
  - preferred_term: Apoptosis
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:26497784
    reference_title: "Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms."
    supports: SUPPORT
    snippet: "Apoptosis of retinal ganglion cells (RGCs) in glaucoma causes progressive visual field loss, making it the primary cause of irreversible blindness worldwide."
    explanation: Establishes that RGC apoptosis is the direct cause of visual field loss in glaucoma, confirming the central role of programmed cell death in disease pathogenesis.
  - reference: PMID:26302410
    reference_title: "Defects in autophagy caused by glaucoma-associated mutations in optineurin."
    supports: SUPPORT
    snippet: "A glaucoma-associated mutant of optineurin, E50K, impairs autophagy as well as vesicle trafficking, leading to death of retinal cells by apoptosis."
    explanation: Links OPTN mutations to RGC apoptosis through impaired autophagy, providing a molecular mechanism for how genetic variants cause retinal ganglion cell death.
  - reference: PMID:37542647
    reference_title: "Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury."
    supports: SUPPORT
    snippet: "Glaucoma is a leading cause of permanent blindness worldwide and is characterized by neurodegeneration linked to progressive retinal ganglion cell (RGC) death, axonal damage, and neuroinflammation."
    explanation: Confirms that RGC death is a hallmark of glaucoma neurodegeneration and highlights the role of neuroinflammation in the degenerative process.
- name: Optic Nerve Degeneration
  description: >
    Loss of ganglion cell axons causes characteristic optic disc
    cupping. Progressive nerve fiber layer loss detectable before
    symptomatic visual field loss.
  locations:
  - preferred_term: Optic Nerve
    term:
      id: UBERON:0000941
      label: cranial nerve II
  - preferred_term: Optic Disc
    term:
      id: UBERON:0001783
      label: optic disc
- name: Trabecular Meshwork Dysfunction
  description: >
    Age-related changes, oxidative stress, and altered extracellular
    matrix reduce outflow facility. Increased resistance to aqueous
    outflow.
  locations:
  - preferred_term: Trabecular Meshwork
    term:
      id: UBERON:0005969
      label: eye trabecular meshwork
  cell_types:
  - preferred_term: Trabecular Meshwork Cell
    term:
      id: CL:0002367
      label: trabecular meshwork cell
  evidence:
  - reference: PMID:10617907
    reference_title: "The myocilin (MYOC) gene expression in the human trabecular meshwork."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Myocilin gene is expressed clearly in the trabecular meshwork cells of both glaucomatous and nonglaucomatous eyes."
    explanation: >-
      Confirms MYOC expression in trabecular meshwork cells, but expression
      alone only indirectly supports dysfunction. In situ RNA hybridization on
      ex vivo human trabecular meshwork specimens, hence IN_VITRO; note the
      signal was present in nonglaucomatous eyes too.
  - reference: PMID:37217093
    reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The prevailing pathogenic mechanism involves a gain of toxic function whereby mutant myocilin aggregates intracellularly instead of being secreted, which causes cell stress and an early timeline for TM cell death, elevated intraocular pressure, and subsequent glaucoma-associated retinal degeneration."
    explanation: >-
      Regraded to PARTIAL: this describes the Mendelian MYOC misfolding
      mechanism, a distinct route to trabecular meshwork cell death, whereas
      this node asserts the age-related change, oxidative stress and altered
      extracellular matrix route. It establishes that trabecular meshwork
      dysfunction raises intraocular pressure but not the specific upstream
      mechanism claimed here, matching the PARTIAL grade already used on the
      companion MYOC expression item. Tagged OTHER because this is a narrative
      review stating the prevailing consensus mechanism rather than reporting
      primary human, animal or cell data.
phenotypes:
- name: Visual Field Loss
  category: Ophthalmological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Peripheral vision first
  phenotype_term:
    preferred_term: Visual Field Defect
    term:
      id: HP:0001123
      label: Visual field defect
  evidence:
  - reference: PMID:26497784
    reference_title: "Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms."
    supports: SUPPORT
    snippet: "Apoptosis of retinal ganglion cells (RGCs) in glaucoma causes progressive visual field loss, making it the primary cause of irreversible blindness worldwide."
    explanation: Directly links RGC apoptosis to progressive visual field loss, the cardinal clinical manifestation of glaucoma.
- name: Optic Disc Cupping
  category: Ophthalmological
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Optic Atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
- name: Elevated Intraocular Pressure
  category: Ophthalmological
  frequency: FREQUENT
  notes: Not present in normal-tension glaucoma
  phenotype_term:
    preferred_term: Elevated IOP
    term:
      id: HP:0012632
      label: Abnormal intraocular pressure
  evidence:
  - reference: PMID:37217093
    reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
    supports: SUPPORT
    snippet: "The prevailing pathogenic mechanism involves a gain of toxic function whereby mutant myocilin aggregates intracellularly instead of being secreted, which causes cell stress and an early timeline for TM cell death, elevated intraocular pressure, and subsequent glaucoma-associated retinal degeneration."
    explanation: Links mutant MYOC to elevated IOP through trabecular meshwork cell death, establishing the mechanistic connection between genetic mutations and the elevated pressure phenotype.
- name: Halos Around Lights
  category: Ophthalmological
  frequency: OCCASIONAL
  notes: More common in angle-closure
  phenotype_term:
    preferred_term: Visual Impairment
    term:
      id: HP:0000505
      label: Visual impairment
- name: Eye Pain
  category: Ophthalmological
  frequency: OCCASIONAL
  notes: Acute angle-closure glaucoma
  phenotype_term:
    preferred_term: Eye Pain
    term:
      id: HP:0200026
      label: Ocular pain
biochemical:
- name: Intraocular Pressure
  presence: Elevated
  context: "Greater than 21 mmHg in most cases"
genetic:
- name: MYOC
  gene_term:
    preferred_term: MYOC
    term:
      id: hgnc:7610
      label: MYOC
  association: Causative
  notes: Primary open-angle glaucoma
  evidence:
  - reference: PMID:37217093
    reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mutations in the gene MYOC account for approximately 5% of cases of primary open angle glaucoma (POAG)."
    explanation: >
      Establishes MYOC as a causative gene for POAG, accounting for a
      significant proportion of cases. Tagged OTHER: this is a narrative review
      restating an established figure rather than reporting primary data.
  - reference: PMID:37217093
    reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "While myocilin is expressed in numerous tissues, mutant myocilin is only associated with disease in the anterior segment of the eye, in the trabecular meshwork."
    explanation: >
      Demonstrates tissue-specific pathogenicity of MYOC mutations in the
      trabecular meshwork of the eye. Tagged OTHER for the same reason as the
      companion item — review synthesis, not primary observation.
- name: OPTN
  gene_term:
    preferred_term: OPTN
    term:
      id: hgnc:17142
      label: OPTN
  association: Causative
  notes: >
    Primarily normal-tension glaucoma. Typed Causative rather than Risk Factor
    because OPTN E50K is generally treated as a dominant causative variant
    rather than a susceptibility allele, which is the more standard reading of
    this gene.

    The NTG-specific source this note previously said was still needed has now
    been supplied: PMID:16043855 reports that all 11 E50K-carrying patients in
    the Moorfields series had normal-tension glaucoma, with quantified normal
    presenting and peak diurnal pressures.

    The full mechanism lives in its own entry, `OPTN-related Open Angle
    Glaucoma` (MONDO:0100553) - the OPTN-TBK1 misfolding lesion, the block in
    autophagic flux and mitophagy in retinal ganglion cells, and the clinical
    course. It is deliberately NOT re-derived here: this umbrella entry keeps
    the generic IOP-driven trabecular-outflow account of adult POAG, which is
    the arm that does NOT apply to the OPTN entity.
  evidence:
  - reference: PMID:26302410
    reference_title: "Defects in autophagy caused by glaucoma-associated mutations in optineurin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Certain mutations in optineurin (gene OPTN) are associated with primary open angle glaucoma."
    explanation: >
      Regraded to PARTIAL: the snippet establishes an association between OPTN
      mutations and primary open-angle glaucoma, but says nothing about
      normal-tension glaucoma, which is the scope this entry records, and
      "associated with" does not by itself settle causative-versus-risk-allele
      typing. Tagged IN_VITRO — the study characterizes autophagy defects in
      cultured cells expressing mutant optineurin.
  - reference: PMID:16043855
    reference_title: "Clinical features and course of patients with glaucoma with the E50K mutation in the optineurin gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All 11 subjects had normal tension glaucoma (NTG), with presenting and highest IOP of 15.3 +/- 3.0 and 16.5 +/- 2.5 mm Hg (+/-SD) on diurnal testing."
    explanation: >
      Supplies the normal-tension-glaucoma-specific association that the note
      on this entry previously recorded as an outstanding gap: every E50K
      carrier in this clinical series had NTG, at quantified normal pressures.
  - reference: PMID:26302410
    reference_title: "Defects in autophagy caused by glaucoma-associated mutations in optineurin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Thus, an optimum level of optineurin-mediated autophagy is crucial for survival of retinal cells, and impaired autophagy is likely to contribute to glaucoma pathogenesis."
    explanation: >
      Explains how OPTN variants contribute to glaucoma through dysregulated
      autophagy in retinal cells. This is the paper's own mechanistic
      conclusion, so SUPPORT stands; the cell-based experimental basis is
      recorded by the IN_VITRO tag.
- name: WDR36
  gene_term:
    preferred_term: WDR36
    term:
      id: hgnc:30696
      label: WDR36
  association: Risk Factor
- name: CAV1/CAV2
  association: Risk Factor
environmental:
- name: Age
  notes: Major risk factor, increases after 40
  evidence:
  - reference: PMID:2056646
    reference_title: "Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rates among blacks ranged from 1.23% in those aged 40 through 49 years to 11.26% in those 80 years or older"
    explanation: "Population-based survey of 5,308 participants, showing a roughly nine-fold prevalence gradient across the age range sampled. PARTIAL for two reasons: the survey enrols only from age 40, so it cannot evidence 40 as a threshold, and its subject is racial variation rather than age."
- name: Family History
  notes: First-degree relatives at ~4-7x increased risk (siblings RR 3.8, parents
    RR 6.3, children RR 6.8)
  evidence:
  - reference: PMID:20858511
    reference_title: "Using the Utah Population Database to assess familial risk of primary open angle glaucoma"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "siblings (RR=3.76 (95% CI 2.66-5.31)), parents (RR=6.25 (95% CI 3.94-9.9)) and children (RR=6.77 (95% CI 3.39-13.5))"
    explanation: "Case-control analysis over 1M linked records. The note previously said 4-9x; the measured first-degree relative risks are 3.8-6.8, so the range has been corrected to what the citation supports."
- name: African Ancestry
  notes: Higher prevalence and severity
  evidence:
  - reference: PMID:24974815
    reference_title: "Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "people of African ancestry were more likely to have POAG than people of European ancestry (OR, 2.80; 95% CrI, 1.83-4.06)"
    explanation: "Meta-analysis of 50 population-based studies, adjusted for age, gender, habitation type and study year. PARTIAL because it evidences the prevalence half of this annotation but not the severity half."
- name: Myopia
  notes: Risk factor for open-angle glaucoma
  evidence:
  - reference: PMID:34648776
    reference_title: "Degree of Myopia and Glaucoma Risk: A Dose-Response Meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For each unit (1-D) increase in myopia, the risk of glaucoma increases by approximately 20%"
    explanation: "Dose-response meta-analysis over 514,265 individuals; the risk accelerates nonlinearly beyond about -6 D, reaching OR 4.14 for high myopia."
- name: Corticosteroid Use
  exposure_term:
    preferred_term: corticosteroid exposure
    term:
      id: ECTO:0000173
      label: exposure to corticosteroid
  notes: Can induce steroid glaucoma
  evidence:
  - reference: PMID:26002945
    reference_title: "Steroid-induced glaucoma and childhood blindness"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 1259 cases of paediatric glaucoma presenting at our centre over 5 years, 59 children (4.7%) were diagnosed with SIG"
    explanation: "Clinical series establishing steroid-induced glaucoma as a distinct entity and quantifying its share of paediatric glaucoma; 87% followed topical steroids prescribed for vernal keratoconjunctivitis."
treatments:
- name: Prostaglandin Analogs
  description: First-line topical drops that increase uveoscleral outflow.
  context: First-line topical intraocular pressure-lowering therapy
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
  evidence:
  - reference: PMID:8942890
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Purpose: To determine efficacy and safety of latanoprost, a prostaglandin analog for glaucoma, during 1 year of treatment."
    explanation: This clinical trial directly supports prostaglandin analog therapy, using latanoprost as a representative first-line agent for glaucoma.
    reference_title: Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups
  - reference: PMID:8942890
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusion: Latanoprost safely and effectively reduces IOP for 1 year in patients of diverse nationalities, providing further evidence for its usefulness in chronic glaucoma therapy."
    explanation: This provides direct human evidence that topical latanoprost produces sustained intraocular pressure lowering in glaucoma therapy.
    reference_title: Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups
- name: Beta-Blockers
  description: Topical beta-blocker drops reduce aqueous humor production.
  context: Alternative or adjunctive topical pressure-lowering therapy
  treatment_term:
    preferred_term: beta-blocker therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: timolol
      term:
        id: CHEBI:39465
        label: timolol
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
  evidence:
  - reference: PMID:16750466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Objective: The objective of this study was to assess the hypotensive efficacy of timolol maleate 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% ophthalmic solution, administered in conjunction with travoprost 0.004%, in patients with primary open-angle laucoma (OAG) or ocular hypertension (OHT) whose intraocular pressure (IOP) did not meet the treatment target using travoprost 0.004% monotherapy."
    explanation: This randomized study directly evaluates topical timolol as an intraocular pressure-lowering treatment in open-angle glaucoma or ocular hypertension.
    reference_title: A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension
  - reference: PMID:16750466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusion: Brinzolamide 1% and timolol maleate 0.5% treatment were both associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when administered as a nonfixed adjuvant to travoprost 0.004% in the treatment of patients with OAG and OHT whose IOP was inadequately controlled with travoprost monotherapy."
    explanation: This supports timolol as an effective adjunctive topical beta-blocker therapy for additional pressure reduction.
    reference_title: A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension
- name: Alpha Agonists
  description: Topical alpha-2 agonist drops reduce aqueous production and modestly increase outflow.
  context: Adjunctive or alternative topical pressure-lowering therapy
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: brimonidine
      term:
        id: CHEBI:3175
        label: brimonidine
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
  evidence:
  - reference: PMID:14660453
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%."
    explanation: This randomized trial directly supports brimonidine as a therapeutic alpha agonist used in primary open-angle glaucoma.
    reference_title: 'Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection'
  - reference: PMID:14660453
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results: IOP reduction was similar for both groups (p<0.05)."
    explanation: >-
      Regraded to PARTIAL: this is a non-difference result between brimonidine
      and timolol in a 16-patient trial, so it shows brimonidine is not
      inferior to an established agent rather than quantifying clinically
      meaningful intraocular pressure lowering on its own.
    reference_title: 'Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection'
- name: Carbonic Anhydrase Inhibitors
  description: Topical carbonic anhydrase inhibitors reduce aqueous humor production.
  context: Adjunctive or alternative topical pressure-lowering therapy
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dorzolamide
      term:
        id: CHEBI:4702
        label: dorzolamide
    - preferred_term: brinzolamide
      term:
        id: CHEBI:3176
        label: brinzolamide
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
  evidence:
  - reference: PMID:16750466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Objective: The objective of this study was to assess the hypotensive efficacy of timolol maleate 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% ophthalmic solution, administered in conjunction with travoprost 0.004%, in patients with primary open-angle laucoma (OAG) or ocular hypertension (OHT) whose intraocular pressure (IOP) did not meet the treatment target using travoprost 0.004% monotherapy."
    explanation: This randomized study directly evaluates brinzolamide, a topical carbonic anhydrase inhibitor, as an IOP-lowering therapy in glaucoma or ocular hypertension.
    reference_title: A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension
  - reference: PMID:16750466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusion: Brinzolamide 1% and timolol maleate 0.5% treatment were both associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when administered as a nonfixed adjuvant to travoprost 0.004% in the treatment of patients with OAG and OHT whose IOP was inadequately controlled with travoprost monotherapy."
    explanation: This supports topical carbonic anhydrase inhibition, represented here by brinzolamide, as an effective adjunctive strategy for lowering intraocular pressure.
    reference_title: A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension
- name: Rho Kinase Inhibitors
  description: Topical rho kinase inhibitors improve trabecular outflow and lower intraocular pressure.
  context: Topical pharmacologic option for additional pressure lowering
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: route of administration
        term:
          id: NCIT:C38114
          label: Route of Administration
      value:
        preferred_term: topical route of administration
        term:
          id: NCIT:C38304
          label: Topical Route of Administration
  evidence:
  - reference: PMID:29199013
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Purpose: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension."
    explanation: This phase 3 clinical program directly supports rho kinase inhibitor therapy using netarsudil in open-angle glaucoma or ocular hypertension.
    reference_title: 'Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)'
  - reference: PMID:29199013
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusions: In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma."
    explanation: This supports netarsudil-based rho kinase inhibition as an effective and tolerated topical treatment option.
    reference_title: 'Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)'
- name: Laser Trabeculoplasty
  description: SLT increases trabecular outflow.
  context: Drop-sparing procedural alternative to first-line medication
  evidence:
  - reference: PMID:30862377
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At 36 months, 74·2% (95% CI 69·3-78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target."
    explanation: This randomized trial supports selective laser trabeculoplasty as an effective drop-sparing treatment strategy in open-angle glaucoma or ocular hypertension.
    reference_title: 'Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial'
- name: Trabeculectomy
  description: Incisional filtration surgery for advanced or medically uncontrolled glaucoma.
  context: Escalation therapy for advanced disease or inadequate control with drops
  treatment_term:
    preferred_term: trabeculectomy
    term:
      id: NCIT:C220170
      label: Surgical Construction of Filtration Bleb
  evidence:
  - reference: PMID:33980505
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interventions: Mitomycin C augmented trabeculectomy (n=227) and escalating medical management with intraocular pressure reducing drops (n=226)"
    explanation: This randomized trial directly evaluates trabeculectomy as a primary interventional treatment for advanced open-angle glaucoma.
    reference_title: 'Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS)'
  - reference: PMID:33980505
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusion: Primary trabeculectomy had similar quality of life and safety outcomes and achieved a lower intraocular pressure compared with primary medication."
    explanation: This supports trabeculectomy as a clinically effective pressure-lowering option in advanced glaucoma.
    reference_title: 'Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS)'
- name: MIGS
  description: Microstent-based and related minimally invasive glaucoma surgery options can reduce medication burden and improve pressure control.
  context: Mild-to-moderate primary open-angle glaucoma, often combined with cataract surgery
  evidence:
  - reference: PMID:33166551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Purpose: To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone."
    explanation: This randomized trial directly studies a representative minimally invasive glaucoma surgery device in primary open-angle glaucoma.
    reference_title: 'Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract'
  - reference: PMID:33166551
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Conclusions: Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at 3 years."
    explanation: This supports MIGS as a pressure-lowering and medication-sparing surgical option in appropriately selected open-angle glaucoma.
    reference_title: 'Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract'
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE301525
  title: Chromatin topology dynamics of dexamethasone-treated trabecular meshwork identifies 78 causal genes for intraocular pressure and primary open angle glaucoma
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MULTI_OMICS
  sample_count: 131
  publication: PMID:41890121
  notes: Identified by GEO DataSets index search for Glaucoma (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001000624
  title: WTCCC2 project Glaucoma (GL) samples
  description: A WTCCC2 genome-wide association study for glaucoma (GL) in Australian individuals of European descent.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:23836780
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Glaucoma"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST001442
  title: Human Optic Nerve Glaucoma and Control Lipidomes
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Glaucoma"). Retrieved 2026-08-02.
- accession: massive:MSV000080838
  title: Comparative shotgun proteomics of aqueous humor for cataract, glaucoma and pseudoexfoliation eye disorders.
  description: The aim of this work was to characterize proteome of aqueous humor from subjects with various eye conditions such as cataract, glaucoma and pseudoexfoliation syndrome by high-resolution chromate-mass-spectrometry. Twenty nine human aqueous humor samples were processed by shotgun proteomics. Data was searched using MaxQuant package. Totally, 263 protein groups were identified. Label-free quantitation reported some differentially expressed proteins in aqueous humor proteome for the aforementioned eye diseases.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Glaucoma"). Retrieved 2026-08-02.
- accession: massive:MSV000081757
  title: Retinal proteomic profiling in the course of experimental glaucoma
  description: Intraocular pressure was elevated through episkleral vein occlusion by thermic cauterization of SD rats. Animals were further sacrificed after different periods of elevated IOP and the retinal proteins were investigated for alterations regarding the relative protein level in this experimental model of glaucoma.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Glaucoma"). Retrieved 2026-08-02.
references:
- reference: DOI:10.20944/preprints202512.0304.v1
  title: 'Cell Motility Dynamics in Glaucoma: Mechanisms, Pathogenic Roles, and Therapeutic Targeting'
  findings: []
- reference: DOI:10.3892/mmr.2025.13757
  title: Research progress on molecular therapy for glaucoma (Review)
  findings: []
- reference: DOI:10.7759/cureus.91633
  title: 'Molecular Gatekeepers of Aqueous Outflow: From Mechanotransduction to Gene Therapy in Trabecular Meshwork Health and Disease'
  findings: []
📚

References & Deep Research

References

3
DOI:10.20944/preprints202512.0304.v1
Cell Motility Dynamics in Glaucoma: Mechanisms, Pathogenic Roles, and Therapeutic Targeting
No top-level findings curated for this source.
DOI:10.3892/mmr.2025.13757
Research progress on molecular therapy for glaucoma (Review)
No top-level findings curated for this source.
DOI:10.7759/cureus.91633
Molecular Gatekeepers of Aqueous Outflow: From Mechanotransduction to Gene Therapy in Trabecular Meshwork Health and Disease
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Glaucoma
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 15

Key Pathophysiology Nodes

  • Elevated Intraocular Pressure
  • Retinal Ganglion Cell Death
  • Optic Nerve Degeneration
  • Trabecular Meshwork Dysfunction
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.20944/preprints202512.0304.v1
  • DOI:10.3892/mmr.2025.13757
  • DOI:10.7759/cureus.91633
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 14 citations 2025-12-18T00:06:27.657515

Disease Pathophysiology Research Report

Target Disease - Disease Name: Glaucoma - MONDO ID: MONDO_0005015 (primary open‑angle glaucoma falls under MONDO_0005015 hierarchy) - Category: Complex

Pathophysiology description (current understanding) Glaucoma comprises optic neuropathies characterized by retinal ganglion cell (RGC) degeneration and optic nerve head (ONH) remodeling. Elevated intraocular pressure (IOP) from impaired aqueous humor outflow via trabecular meshwork (TM) and Schlemm’s canal (SC) is a major risk driver; however, IOP‑independent mechanisms, including mitochondrial dysfunction, neuroinflammation, and genetic susceptibilities (e.g., OPTN/TBK1, SIX6) also contribute, particularly in normal‑tension glaucoma. A central theme emerging from recent work is a feed‑forward coupling of profibrotic TGF‑β signaling with mechanotransduction pathways (Hippo‑YAP/TAZ, integrin–FAK, TRPV4 and PIEZO1 channels) that stiffens TM/SC and ONH tissues, impairs cellular motility and adaptability, and elevates outflow resistance. Parallel mitochondrial and axonal transport stress in RGCs, and glial‑mediated neuroinflammation with inflammasome activation and blood‑retinal barrier (BRB) disruption, drive progressive axonopathy and vision loss (2023–2025 literature) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15, wang2025researchprogresson pages 1-2).

1) Core pathophysiology - Dysregulated profibrotic signaling and mechanotransduction in the outflow tract: Elevated TGF‑β2 promotes ECM deposition (collagens, fibronectin), cytoskeletal stress fibers/CLANs, and EndMT in SC; downstream RhoA/ROCK and Hippo effectors YAP/TAZ link biochemical cues to stiffness and pro‑fibrotic transcription. Mechanosensitive channels TRPV4 and PIEZO1 transduce pressure/flow into Ca2+ signaling, contractility, and further ECM remodeling, generating a mechano‑biochemical feed‑forward loop that increases outflow resistance and IOP (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Integrin–FAK focal adhesion signaling: Integrins (e.g., ITGA9) and FAK coordinate ECM–cytoskeleton coupling in TM/SC cells; aberrant activation aligns with tissue stiffness and impaired motility; ROCK inhibition can partly restore motility and outflow (rusciano2025cellmotilitydynamics pages 11-13, singh2025moleculargatekeepersof pages 2-3). - RGC mitochondrial dysfunction and axonopathy: High metabolic demand makes RGCs vulnerable to oxidative stress, disrupted oxidative phosphorylation, and mitophagy dysregulation; impaired axonal transport at the lamina cribrosa and energy failure contribute to early axon degeneration, progressing to soma loss (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2). - Neuroinflammation and BRB dysfunction: Chronic activation of microglia and astrocytes, upregulation of cytokines (TNF‑α, IL‑1β), and inflammasome (e.g., NLRP3) involvement propagate neurodegeneration. BRB compromise amplifies leukocyte trafficking and inflammatory milieu at retina/ONH (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2).

2) Key molecular players - Genes/Proteins: MYOC (mutant secretion defects → ER stress/UPR in TM and IOP elevation), OPTN and TBK1 (autophagy/mitophagy signaling and innate immunity; variants linked to NTG and RGC vulnerability), SIX6 (developmental transcription factor linked to optic nerve/RGC susceptibility), YAP1/TAZ (Hippo mechanotransduction), TGFB2 (profibrotic driver), TRPV4 and PIEZO1 (mechanosensitive channels), ITGA9/FAK (integrin–FAK adhesion signaling), NLRP3 (inflammasome) (palanivel2025understandingtherole pages 25-30, singh2025moleculargatekeepersof pages 2-3, wang2025researchprogresson pages 1-2, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15, rusciano2025cellmotilitydynamics pages 6-7). - Chemical entities: ROCK inhibitors (cytoskeletal relaxation), agents modulating TGF‑β/ECM, antioxidants/mitochondrial support (e.g., nicotinamide discussed in 2023–2024 literature), emerging anti‑inflammatory strategies targeting inflammasome/cytokine axes (rusciano2025cellmotilitydynamics pages 13-15, wang2025researchprogresson pages 1-2). - Cell types: TM cells and SC endothelium (outflow resistance), astrocytes and lamina cribrosa fibroblasts at the ONH, microglia (neuroinflammation), RGCs (primary neuronal loss) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 30-34). - Anatomical locations: Trabecular meshwork (UBERON:0001772), Schlemm’s canal (UBERON:0001808), optic nerve head/lamina cribrosa (UBERON:0001801), retina (UBERON:0000966) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 6-7).

3) Biological processes (GO) disrupted - ECM organization and fibrosis; EndMT/epithelial–mesenchymal transitions; mechanotransduction and response to mechanical stimulus; focal adhesion assembly and cytoskeletal organization; calcium ion transmembrane transport; ER stress and unfolded protein response; autophagy/mitophagy; inflammatory response and inflammasome activation; leukocyte adhesion and vascular responses (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 25-30, wang2025researchprogresson pages 1-2).

4) Cellular components (sites of key processes) - Cell–ECM adhesions/focal adhesions (integrin–FAK complexes in TM/SC), plasma membrane mechanosensors (TRPV4/PIEZO1), nucleus (YAP/TAZ transcriptional co‑activators), ER (MYOC misfolding, UPR), mitochondria (RGC bioenergetics/mitophagy), extracellular space (ECM remodeling), tight junctions/inner BRB (endothelial/pericyte barriers) (singh2025moleculargatekeepersof pages 2-3, rusciano2025cellmotilitydynamics pages 6-7, wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 30-34).

5) Disease progression sequence - Initiation in the outflow tract: TGF‑β2 elevation and mechanotransduction abnormalities in TM/SC promote ECM deposition, cytoskeletal stiffening, and reduced motility, increasing outflow resistance and IOP (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Biomechanical stress at the ONH: Elevated IOP and scleral/laminar stiffness induce axoplasmic flow blockade and axonal injury; astrocyte reactivity and ECM remodeling further compromise axon bundles (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Early RGC axonopathy to soma loss: Mitochondrial dysfunction and impaired transport precipitate distal axon degeneration, followed by RGC apoptosis/other death modes; microglial/astroglial activation and inflammasome signaling accelerate neurodegeneration (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2). - IOP‑independent contributors: Genetic susceptibilities (OPTN/TBK1/SIX6) and vascular/neuroinflammatory factors drive disease even with normal tension, highlighting dual IOP‑dependent/independent components (wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 25-30).

6) Phenotypic manifestations (clinical) - Structural: ONH cupping and lamina cribrosa remodeling; RNFL thinning; TM stiffening and reduced motion (advanced imaging) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Functional: Progressive visual field loss; reduced contrast sensitivity; electrophysiologic deficits linked to RGC dysfunction (wang2025researchprogresson pages 1-2).

Gene/protein annotations with ontology terms - HGNC: MYOC; GO: ER stress response, protein folding; CL: TM cell; UBERON: TM; Mechanism: ER stress/UPR with mutant MYOC; Evidence: Wang 2025 (review) (wang2025researchprogresson pages 1-2). - HGNC: OPTN; GO: selective autophagy, mitophagy; CL: RGC; UBERON: retina; Mechanism: autophagy dysfunction in NTG; Evidence: Wang 2025 (wang2025researchprogresson pages 1-2). - HGNC: TBK1; GO: regulation of autophagy/innate signaling; CL: microglia/RGC; UBERON: retina; Mechanism: OPTN–TBK1 axis; Evidence: Wang 2025 (wang2025researchprogresson pages 1-2). - HGNC: SIX6; GO: eye development; CL: retinal progenitors; UBERON: retina/ONH; Mechanism: developmental susceptibility; Evidence: Rusciano 2025 preprint review (rusciano2025cellmotilitydynamics pages 11-13). - HGNC: YAP1; GO: response to mechanical stimulus, transcription co‑activation; CL: TM/SC/astrocyte; UBERON: TM/ONH; Mechanism: Hippo–YAP/TAZ; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13). - HGNC: TGFB2; GO: ECM organization, SMAD signaling; CL: TM/SC; UBERON: TM/SC; Mechanism: fibrosis and EndMT; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13). - HGNC: PIEZO1; GO: mechanosensory ion channel activity; CL: SC endothelium; UBERON: SC; Mechanism: pressure/flow sensing; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - HGNC: TRPV4; GO: calcium transport, cytoskeleton regulation; CL: TM; UBERON: TM; Mechanism: contractility and OHT; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 13-15). - HGNC: ITGA9/PTK2(FAK); GO: cell adhesion/focal adhesion; CL: TM/SC; UBERON: TM/SC; Mechanism: integrin–FAK; Evidence: Singh 2025 (singh2025moleculargatekeepersof pages 2-3). - HGNC: NLRP3; GO: inflammasome activation; CL: microglia; UBERON: retina/ONH; Mechanism: pyroptosis/neuroinflammation; Evidence: Wang 2025 (wang2025researchprogresson pages 1-2) and pathophysiology summaries (palanivel2025understandingtherole pages 30-34).

Cell type involvement (CL terms) - CL:0000740 retinal ganglion cell; CL:0000129 microglial cell; CL:0000746 astrocyte; TM cell (human ocular TM cell, commonly curated as ocular fibroblast-like cell); SC endothelial cell (venous/lymphatic-like endothelium) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 30-34).

Anatomical locations (UBERON terms) - UBERON:0001772 trabecular meshwork; UBERON:0001808 Schlemm’s canal; UBERON:0001801 optic nerve head; UBERON:0000966 retina (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13).

Chemical entities (CHEBI) and modalities - CHEBI: ROCK inhibitors (e.g., netarsudil class) to relax TM/SC cytoskeleton; anti‑fibrotics targeting TGF‑β/ECM; mitochondrial support (e.g., nicotinamide); emerging anti‑inflammatory/anti‑inflammasome approaches (rusciano2025cellmotilitydynamics pages 13-15, wang2025researchprogresson pages 1-2).

Evidence items (recent) - Mechanotransduction/fibrosis nexus and therapeutic implications (YAP/TAZ, TRPV4, PIEZO1; ROCK inhibition; diagnostic elastography): Rusciano 2025 preprint review (Dec 2025). URL: https://doi.org/10.20944/preprints202512.0304.v1 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - TM mechanotransduction and gene therapy framing (integrin–FAK, TRPV4/PIEZO1; CRISPR prospects): Singh 2025 Cureus (Sep 2025). URL: https://doi.org/10.7759/cureus.91633 (singh2025moleculargatekeepersof pages 1-2, singh2025moleculargatekeepersof pages 2-3). - Mitochondrial dysfunction and multimodal cell‑death in RGCs; oxidative stress; molecular therapy directions: Wang 2025 Molecular Medicine Reports (Nov 2025). URL: https://doi.org/10.3892/mmr.2025.13757 (wang2025researchprogresson pages 1-2). - Neuroinflammation and inflammasome/BRB themes, with cytokines in glaucomatous milieu: Palanivel 2025 thesis review excerpts (2025) (palanivel2025understandingtherole pages 30-34, palanivel2025understandingtherole pages 25-30).

Current applications and real‑world implementations - IOP lowering remains standard of care; however, cytoskeletal modulators (ROCK inhibitors) directly target TM/SC mechanobiology and can reduce EndMT/fibrosis‑linked resistance; device‑based outflow restoration (MIGS) complements pharmacology; diagnostics increasingly assess TM stiffness/motion to stratify disease (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15, singh2025moleculargatekeepersof pages 2-3). - Gene therapy proof‑of‑concepts: CRISPR strategies against MYOC have preclinical efficacy in reducing ER‑stress–mediated TM dysfunction and IOP in transgenic models; these approaches seek durable correction beyond symptomatic pressure reduction (context discussed in reviews) (wang2025researchprogresson pages 1-2, singh2025moleculargatekeepersof pages 2-3). - Neuroprotection pipelines target mitochondrial resilience (e.g., nicotinamide) and modulate neuroinflammation (inflammasome/cytokines, microglial responses). Clinical translation requires biomarkers to identify IOP‑independent progression (wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 30-34).

Expert opinions and analysis (authoritative perspectives) - Mechanobiology‑centered frameworks argue glaucoma reflects failure of tissue adaptability under chronic mechanical and biochemical stress, necessitating combined anti‑fibrotic, mechanotransduction‑targeting, and pressure‑lowering strategies; integration of OCT‑based elastography and AI may enable personalized, pre‑emptive treatment (Rusciano preprint 2025) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Molecular therapy reviews advocate tandem approaches: outflow repair (TM‑directed) plus RGC neuroprotection targeting mitochondria, oxidative stress, and programmed cell death pathways, particularly for normal‑tension disease (Wang 2025) (wang2025researchprogresson pages 1-2).

Relevant statistics and data - Genetic screening studies identify hypomorphic/rare variants across glaucoma genes (e.g., SIX6, OPTN, CYP1B1), supporting complex polygenic risk; multi‑ethnic GWAS have delineated IOP‑dependent and IOP‑independent components, aligning with clinical heterogeneity (summarized in 2025 review; additional 2024 studies cited therein) (wang2025researchprogresson pages 1-2).

Embedded ontology artifact | Gene/Protein (HGNC) | Key role in glaucoma (short) | GO Biological Process terms | Cell type (CL id/name) | Anatomy (UBERON id/name) | Pathway / Mechanism keywords | Evidence (DOI/URL + year) | |---|---|---|---|---|---|---| | MYOC | TM ECM homeostasis; mutant MYOC → ER stress, TM cell death, ↑IOP | protein folding; ER stress response; secretion | trabecular meshwork cell | UBERON:0001772 trabecular meshwork | ER stress, UPR, autophagy deregulation, TM fibrosis | https://doi.org/10.3892/mmr.2025.13757 (2025) (wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 25-30) | | OPTN | Autophagy receptor; OPTN variants → RGC vulnerability (NTG) | selective autophagy; vesicle-mediated transport | CL:0000740 retinal ganglion cell | UBERON:0000966 retina | mitophagy/autophagy, protein aggregation, neuroinflammation | https://doi.org/10.3892/mmr.2025.13757 (2025) (palanivel2025understandingtherole pages 25-30, wang2025researchprogresson pages 1-2) | | TBK1 | Regulates autophagy and innate signaling; duplications linked to glaucoma | regulation of autophagy; innate immune signaling | microglial cell (CL:0000129) / RGCs | UBERON:0000966 retina | TBK1-OPTN autophagy axis, NF-κB signaling | https://doi.org/10.3892/mmr.2025.13757 (2025) (palanivel2025understandingtherole pages 25-30, wang2025researchprogresson pages 1-2) | | SIX6 | Developmental regulator; risk allele affects RGC development & susceptibility | eye development; regulation of transcription | retinal progenitor / RGC precursors | UBERON:0000966 retina | developmental susceptibility, CDKN2A/B network | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 25-30) | | YAP1 (Hippo) | Mechanotransduction effector; mediates stiffness-induced TM/SC changes | regulation of transcription, response to mechanical stimulus | astrocyte (CL:0000746) / TM cells | UBERON:0001772 trabecular meshwork; UBERON:0001801 optic nerve head | Hippo–YAP/TAZ, mechanoresponsive transcription, fibrosis | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13) | | TGFB2 | Profibrotic cytokine elevated in AH; drives ECM deposition in TM/SC | extracellular matrix organization; SMAD signaling | trabecular meshwork cell / SC endothelium | UBERON:0001772 trabecular meshwork; UBERON:0001808 Schlemm's canal | TGF-β/SMAD, EndMT, ECM remodeling, fibrosis | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13) | | PIEZO1 | Mechanosensitive ion channel in SC/TM; links pressure to endothelial responses | response to mechanical stimulus; ion transport | Schlemm's canal endothelial cell | UBERON:0001808 Schlemm's canal | mechanotransduction, Ca2+ influx, ANGPT2–integrin loop | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15) | | TRPV4 | Mechanosensitive Ca2+ channel; mediates TM contractility and OHT | calcium ion transport; regulation of cytoskeleton | trabecular meshwork cell | UBERON:0001772 trabecular meshwork | TRPV4-mediated contractility, Ca2+ signaling, interaction with TGF-β | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 13-15, rusciano2025cellmotilitydynamics pages 11-13) | | ITGA9 / FAK (PTK2) | Integrin–FAK adhesion signaling; regulates TM/SC cell adhesion & remodeling | cell adhesion; focal adhesion assembly; signal transduction | endothelial / trabecular meshwork cell | UBERON:0001808 Schlemm's canal; UBERON:0001772 trabecular meshwork | integrin–FAK, mechanotransduction, ECM–cytoskeleton coupling | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, singh2025moleculargatekeepersof pages 2-3) | | NLRP3 | Inflammasome sensor driving retinal inflammation and pyroptosis | inflammasome activation; inflammatory response | microglial cell (CL:0000129) | UBERON:0000966 retina; UBERON:0001801 optic nerve head | NLRP3 inflammasome, IL-1β release, neuroinflammation | https://doi.org/10.3892/mmr.2025.13757 (2025) (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2) | | LOXL1 | ECM crosslinking enzyme; linked to exfoliation and ECM stiffening | extracellular matrix organization; collagen fibril crosslinking | extracellular matrix / fibroblast-like TM cells | UBERON:0001772 trabecular meshwork | ECM crosslinking, increased stiffness, outflow resistance | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 25-30) | | VCAM1 | Endothelial adhesion molecule; connects vascular inflammation to ONH injury | leukocyte adhesion; cell–cell adhesion | vascular endothelium / SC endothelium | UBERON:0001801 optic nerve head; UBERON:0001808 Schlemm's canal | endothelial activation, immune cell recruitment, vascular dysregulation | https://doi.org/10.7759/cureus.91633 (2025) (singh2025moleculargatekeepersof pages 2-3, wang2025researchprogresson pages 1-2) |

Table: Ontology-ready table mapping 12 key genes/proteins to their roles, GO processes, cell types (CL), anatomical sites (UBERON), core mechanisms, and recent evidence (DOIs/years) to support mechanistic curation for a disease knowledge base.

Limitations - Some mechanistic details derive from 2025 peer‑reviewed reviews and preprints synthesized from primary literature 2021–2024; where specific 2023–2024 clinical trials and numeric outcomes are requested, additional targeted database queries would refine statistics (rusciano2025cellmotilitydynamics pages 11-13, wang2025researchprogresson pages 1-2).

References with URLs and dates (selection) - Rusciano D, et al. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Preprint. Dec 2025. https://doi.org/10.20944/preprints202512.0304.v1 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15) - Singh P, et al. Molecular gatekeepers of aqueous outflow: from mechanotransduction to gene therapy. Cureus. Sep 2025. https://doi.org/10.7759/cureus.91633 (singh2025moleculargatekeepersof pages 1-2, singh2025moleculargatekeepersof pages 2-3) - Wang W, et al. Research progress on molecular therapy for glaucoma (Review). Mol Med Rep. Nov 2025. https://doi.org/10.3892/mmr.2025.13757 (wang2025researchprogresson pages 1-2) - Palanivel V. Understanding the role of neuropeptide Y in glaucoma. 2025. (Excerpts) (palanivel2025understandingtherole pages 30-34, palanivel2025understandingtherole pages 25-30)

References

  1. (rusciano2025cellmotilitydynamics pages 6-7): Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, and José Fernando Maya-Vetencourt. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Unknown journal, Dec 2025. URL: https://doi.org/10.20944/preprints202512.0304.v1, doi:10.20944/preprints202512.0304.v1.

  2. (rusciano2025cellmotilitydynamics pages 11-13): Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, and José Fernando Maya-Vetencourt. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Unknown journal, Dec 2025. URL: https://doi.org/10.20944/preprints202512.0304.v1, doi:10.20944/preprints202512.0304.v1.

  3. (rusciano2025cellmotilitydynamics pages 13-15): Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, and José Fernando Maya-Vetencourt. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Unknown journal, Dec 2025. URL: https://doi.org/10.20944/preprints202512.0304.v1, doi:10.20944/preprints202512.0304.v1.

  4. (wang2025researchprogresson pages 1-2): Weiwei Wang, Gangwei Cheng, Qi Zhou, Sheng Wang, and Linyi Zhang. Research progress on molecular therapy for glaucoma (review). Molecular Medicine Reports, 33:1-10, Nov 2025. URL: https://doi.org/10.3892/mmr.2025.13757, doi:10.3892/mmr.2025.13757. This article has 0 citations and is from a peer-reviewed journal.

  5. (singh2025moleculargatekeepersof pages 2-3): Priti Singh, Samendra Karkhur, Vidhya Verma, Saroj Gupta, and Arushi Beri. Molecular gatekeepers of aqueous outflow: from mechanotransduction to gene therapy in trabecular meshwork health and disease. Cureus, Sep 2025. URL: https://doi.org/10.7759/cureus.91633, doi:10.7759/cureus.91633. This article has 1 citations and is from a poor quality or predatory journal.

  6. (palanivel2025understandingtherole pages 30-34): V Palanivel. Understanding the role of neuropeptide y in ameliorating the degenerative changes in glaucoma. Unknown journal, 2025.

  7. (palanivel2025understandingtherole pages 25-30): V Palanivel. Understanding the role of neuropeptide y in ameliorating the degenerative changes in glaucoma. Unknown journal, 2025.

  8. (singh2025moleculargatekeepersof pages 1-2): Priti Singh, Samendra Karkhur, Vidhya Verma, Saroj Gupta, and Arushi Beri. Molecular gatekeepers of aqueous outflow: from mechanotransduction to gene therapy in trabecular meshwork health and disease. Cureus, Sep 2025. URL: https://doi.org/10.7759/cureus.91633, doi:10.7759/cureus.91633. This article has 1 citations and is from a poor quality or predatory journal.